![](/img/cover-not-exists.png)
187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial
Jean-Pierre Bronowicki, Denis Ouzan, Arnaud Tzanck, Tarik Asselah, Herve Desmorat, Jean-Pierre Zarski, Juliette Foucher, Marc Bourliere, Christophe Renou, Albert Tran, Pascal Melin, Christophe Hezode,Volume:
38
Year:
2003
Language:
english
DOI:
10.1016/s0270-9139(03)80230-6
File:
PDF, 233 KB
english, 2003